Couverture de Team Powdered Donut™ Podcast

Team Powdered Donut™ Podcast

Team Powdered Donut™ Podcast

De : Gary Thompson
Écouter gratuitement

Offres de saison | 0,99 € par mois pendant les 3 premiers mois

5,99 €/mois par la suite. Des conditions s’appliquent. Annulation mensuelle possible.
Over the past ten years, Gary has honored his late wife, Maureen’s, memory by delivering bags of powdered donuts to meaningful places each year on October 21, the day of her passing. What began as a way to turn grief into joy has sparked powerful connections and moments of healing. Team Powdered Donut™ takes this tradition and makes it about all of us. "One Story. One Moment. One Donut at a time." The podcast is going "on the air" ahead of Team Powdered Donut heading out on the road via Airstream® in 2026 to visit all 73 NCI-designated comprehensive cancer centers and other meaningful locations along the way. At every stop, powdered donuts will be shared and stories will be collected – echoing the spirit of StoryCorps® – with a mobile podcast studio in the Airstream in which Gary will travel. From patients to those who love them, from oncologists to their healthcare teams, stories will be captured and shared along the way.Copyright 2026 Gary Thompson Sciences sociales Écritures et commentaires de voyage
Épisodes
  • From Childhood Cancer to Personalized Care. Reimagining the Future of Cancer Treatment. | Dr. Christian Capitini, Director, UW Health Carbone Comprehensive Cancer Center

    From Childhood Cancer to Personalized Care. Reimagining the Future of Cancer Treatment. | Dr. Christian Capitini, Director, UW Health Carbone Comprehensive Cancer Center
    Oct 27 2026

    Summary

    In this episode, Christian Capitini, a pediatric oncologist and cancer researcher, shares insights into the future of cancer immunotherapy, the promise of CAR T cell therapy, and the importance of collective research efforts to transform childhood cancer treatment.

    Key Topics

    • The science behind CAR T cell therapy and its impact on leukemia treatment
    • The importance of collaborative research in advancing cancer care
    • The role of immune system understanding in developing new therapies
    • The significance of early research experiences in shaping medical careers
    • The challenges and opportunities in treating solid tumors with immunotherapy
    • The importance of patient and family-centered care in pediatric oncology
    • Future directions in cancer research including genomics and personalized medicine
    • The impact of clinical trials on treatment options and outcomes
    • The psychosocial aspects of cancer care and the importance of holistic treatment approaches

    Sound Bites

    • "We get cancer all the time, but our immune system keeps it in check"
    • "CAR T cells are genetically engineered to recognize and kill cancer"
    • "We are all in this together, fighting cancer as a community"

    Chapters

    • 00:00 Introduction and guest background
    • 01:34 Christian's journey into cancer research
    • 02:23 Balancing family, recreation, and professional dreams
    • 05:01 The origins of cancer immunotherapy and immune surveillance
    • 07:17 High school research experiences and their influence
    • 10:13 Motivation for specializing in pediatric oncology
    • 12:05 The power of research collaboration in childhood cancer
    • 15:21 Demystifying clinical trials and research participation
    • 21:09 Understanding CAR T cell therapy and its breakthroughs
    • 24:35 Overcoming cancer cell resistance and relapse
    • 28:32 Future directions in immunotherapy and personalized medicine
    • 35:45 Core memories and the human side of cancer treatment
    • 42:23 The importance of communication and family-centered care
    • 48:32 The vision for pediatric oncology in the next decade
    • 54:21 The role of research in transforming cancer care

    Keywords

    cancer immunotherapy, CAR T cell therapy, pediatric oncology, cancer research, immunology, childhood cancer, medical innovation, clinical trials, cancer treatment advances
    Afficher plus Afficher moins
    1 h et 1 min
  • One Pack. One Purpose. Discovering Cures, Elevating Every Life. | Dr. Yolanda Sanchez, Director, University of New Mexico Comprehensive Cancer Center

    One Pack. One Purpose. Discovering Cures, Elevating Every Life. | Dr. Yolanda Sanchez, Director, University of New Mexico Comprehensive Cancer Center
    Oct 20 2026

    Summary

    In this episode, Dr. Yolanda Sanchez, Director and CEO of the University of New Mexico Comprehensive Cancer Center, shares her journey from childhood to leading a major cancer research institution. She discusses the science of DNA damage, the future of cancer treatment, and the importance of community and collaboration in the fight against cancer.

    Powerful Sound Bites

    • "Tumor cells have a lot of damage and inherently they have to lower the threshold of this alert system."
    • "The biggest privilege is seeing something that is going to help people live longer."
    • "Patients look to us for hope, not just data." Chapters 00:00 Introduction to Yoli Sanchez and her journey

    Chapters

    • 02:05 Her role as CEO and director of the cancer center
    • 02:41 Yoli's hobbies and personal passions
    • 03:33 Her dreams for cancer treatment and access 05:00 Her background in science and early career
    • 07:16 The moment that sparked her interest in biomedical research
    • 10:48 The importance of DNA damage in cancer biology
    • 13:34 Preventing cancer through early intervention and vaccines
    • 15:12 Understanding the complexity of cancer as many diseases
    • 21:28 The journey from discovery to patient treatment
    • 24:34 The emotional impact of breakthroughs in cancer research 26:24 Leadership in a large cancer center
    • 30:31 Yoli's significance as the first Hispanic woman leading an NCI center
    • 32:54 Addressing geographic and healthcare disparities in New Mexico
    • 36:29 The 'We Can' campaign and its message of hope
    • 37:08 The human side of cancer care and patient experience
    • 39:53 The role of compassion and community in healing
    • 44:11 The importance of collaboration across cancer centers
    • 48:41 Yoli's one thing: advancing cancer research and care
    • 49:49 Changing perceptions of cancer as a beginning, not an end

    Who Is Yolanda Sanchez, PhD?

    Director and CEO, The University of New Mexico Comprehensive Cancer Center Professor of Molecular Medicine, Department of Internal Medicine, University of New Mexico School of Medicine The Maurice and Marguerite Liberman Distinguished Chair in Cancer Research

    Dr. Yolanda (Yoli) Sanchez is the first Latina/Hispanic woman to lead a National Cancer Institute-designated Comprehensive Cancer Center. Dr. Sanchez is an international expert in DNA damage response pathways. Her research also focused on early drug discovery. Prior to joining The University of New Mexico, Dr. Sanchez served as the Associate Director of Basic Sciences at Dartmouth Cancer Center, another NCI-designated Comprehensive Cancer Center. She was also tenured faculty at the University of Cincinnati College of Medicine, where she was named a PEW Scholar in 2001.

    As Director and CEO of the UNM Comprehensive Cancer Center (UNMCCC), Dr. Sanchez oversees all cancer research and cancer clinical programs at The University of New Mexico, covering all schools, colleges, departments, and facilities including ambulatory and inpatient cancer clinical services. Dr. Sanchez collaborates with leadership at UNM, the UNM Health Sciences Center and UNM Health, as well as the New Mexico state legislature and Governor to bring the latest cancer prevention, diagnostics, and therapeutics to New Mexicans. Dr. Sanchez is committed to broadening the makeup of the leadership at UNMCCC and at other NCI-designated cancer centers in the nation.
    Afficher plus Afficher moins
    54 min
  • Why Ask "Y?" - Curiosity With Purpose and Passion is the Key To Discovery. | Dr. Dan Theodorescu, Director, University of Arizona Comprehensive Cancer Center

    Why Ask "Y?" - Curiosity With Purpose and Passion is the Key To Discovery. | Dr. Dan Theodorescu, Director, University of Arizona Comprehensive Cancer Center
    Oct 13 2026
    Summary In this episode, Dr. Dan Theodorescu discusses his groundbreaking research into chromosome loss and its implications for cancer treatment and prevention. We explore the themes of convergence, community, and the human stories behind scientific discovery, highlighting how interdisciplinary efforts can lead to transformative advances in cancer biology. Key Topics • Chromosome loss and its role in cancer aggressiveness • Convergence of disciplines in cancer research • The impact of Dr. Theodorescu's research on immunotherapy • The strategic focus on convergence to health at U of A • The importance of community and human connection in science Takeaways • Chromosome loss can make cancers more aggressive but also opens new treatment avenues • Interdisciplinary convergence accelerates cancer research and innovation • Dr. Theodorescu's research could reshape cancer risk assessment and prevention • Community and human connection are vital in driving scientific progress • Dedication to patient-centered research is at the core of cancer innovation Articles • Beyond sex determination: the Y chromosome in male cancers | Nature | May 21, 2026 (https://www.nature.com/articles/s41568-026-00935-x) • X and Y chromosomes as determinants of aging and disease | Science | October 1, 2026 (https://www.science.org/doi/10.1126/science.aeh0145) Who Is Dr. Dan Theodorescu? Dan Theodorescu MD PhD is the Nancy C. and Craig M. Berge Director of the University of Arizona Comprehensive Cancer Center. A urologic oncologist and physician scientist trained at University of Toronto and Memorial Sloan Kettering Cancer Center, Theodorescu’s pioneering convergence of cell, computational, and translational biology led to the discovery of regulators of tumor growth, metastasis, and therapeutic response. His seminal discovery that loss of the Y chromosome, and specific genes it encodes, by tumors and immune cells drives cancer progression through immune evasion illuminated the underlying functional consequences of this long-standing genetic alteration. This represents a paradigm shifting series of discoveries with far reaching implications for immune checkpoint blockade, CAR-T cell therapies and sex specific cancer biology. His penchant for novel cancer-related discovery is also demonstrated by developing pioneering computational technologies that led to a “first in class” inhibitor to the RalGTPase, a protein involved in cancer metastasis, now in commercial development. His development of the COXEN algorithm and the revolutionary AI-driven Molecular Twin Precision Oncology Platform that creates computational replicas of patients and their tumors using tumor-host multi-omic data, introduced mechanistically grounded, predictive tools that underwent proof-of-concept clinical trials, reshaping concepts of biomarker design, drug selection, and individualized treatment. He has consistently translated his fundamental discoveries into first in class therapeutic candidates, including DDR2 directed immunotherapy sensitizers, and NPEPPS, a new target whose inhibition overcomes platinum resistance. His laboratory has been continuously funded by the NCI soon after his first faculty appointment in 1995. In 2025 he received an R35 Outstanding Investigator Award (OIA) from the National Cancer Institute (NCI). Theodorescu has been a PI of an NCI P01 and a project leader in a SPORE as well as a current MPI and project leader U54 and P01. In 2021 he was awarded the inaugural and only national Director Award for a DOD Convergence Science Virtual Cancer Center (https://csvcc.org/). He has elected to the American Society for Clinical Investigation (ASCI), Association of American Physicians (AAP), the American Association of Genitourinary Surgeons (AAGUS), the American Surgical Association (ASA) and the National Academy of Medicine (NAM). Theodorescu is a Fellow of the American Association for the Advancement of Science (AAAS) and served on the National Cancer Policy Forum (NCPF) of the National Academies of Science, Engineering and Medicine and on the NCI’s Board of Scientific Counselors (BSC). He is the founding co-editor in chief of Bladder Cancer, the first journal focused on this disease. Since 2025 Theodorescu is the Nancy C. and Craig M. Berge Director of the UofA Comprehensive Cancer Center. Previously, Theodorescu was Director, University of Colorado Comprehensive Cancer Center. He led the center through two NCI Cancer Center Support Grant (CCSG P30) renewals. Under his leadership, the center was elected to the National Comprehensive Cancer Network (NCCN) and Oncology Research Information Exchange Network (ORIEN) and awarded a LAPS/NCI grant. Theodorescu worked with State of Colorado legislators to secure yearly center funding. At the federal level, he worked on parts the 21st Century Cures Act passed in 2016. He was appointed a Distinguished University Professor in 2017, one of less than 100 such individuals in the ...
    Afficher plus Afficher moins
    57 min
adbl_web_anon_alc_button_suppression_t1
Aucun commentaire pour le moment